Regenerative medicine
Obesity and metabolism
At Procelk®, metabolic medicine begins with a fundamental idea: health starts in the way your cells produce and use energy. When that balance is disrupted, the body begins to show it in different ways, from chronic inflammation, insulin resistance, and hormonal changes, to difficulty regulating weight, accelerated aging processes, or alterations in reproductive health.
That is why this approach seeks to identify how your body is functioning at the cellular and metabolic level in order to intervene in a personalized, precise, and clinically grounded way.
The essentials
Metabolic medicine, in brief
What is it?
Metabolic medicine is a clinical approach focused on evaluating and optimizing the way your body processes energy.
At Procelk, this is carried out through tools such as the Longevity Test, which helps determine the biological age of your cells and your current metabolic status, along with personalized interventions aimed at correcting imbalances and improving the biological environment at its core.
Rather than treating isolated symptoms, this approach focuses on strengthening the biological foundation upon which your health is built.
Who is it for?
It is for people who want to better understand their current health status, prevent metabolic decline, or address conditions that may have an energetic and cellular basis.
It may benefit patients with insulin resistance, type 2 diabetes, obesity, polycystic ovary syndrome, chronic inflammation, hormonal imbalances, climacteric symptoms, andropause, or cardiovascular risk. It is also a valuable tool for those who want to optimize their well-being, longevity, and, in some cases, improve the way their body responds before a reproductive or regenerative treatment.
How is it done?
The process begins with a comprehensive metabolic evaluation, in which medical history, body composition, biochemical studies, and lifestyle factors are reviewed.
From there, a personalized strategy is defined according to each patient’s needs. The approach includes clinical support, nutritional adjustments, habit education, and periodic follow-up to monitor results and adapt the plan as the body responds. In this way, each intervention is built on real data, with clear and measurable goals.
Clinical benefits
At Procelk®, we treat metabolism from a deeper perspective to help you regain balance, improve the way your body responds, and build more stable health from within.
Clinical benefit
Hormonal regulation
Improvements in sexual satisfaction
When intimate life changes—less desire, less response, or less satisfaction—it does not only affect sexuality, but also confidence and personal well-being. Nguyen Thanh and collaborators published a phase I/IIa clinical trial in Stem Cell Reviews and Reports (2021) involving 31 people with reduced sexual activity, where they evaluated the intravenous infusion of an autologous cellular component derived from adipose tissue. After treatment, all participants reported greater sexual satisfaction, and in men, an increase in testosterone levels was observed and maintained for up to 6 months. No serious adverse events were recorded during follow-up.
This suggests that this type of approach may support biological processes related to sexual response, helping restore part of the well-being and confidence involved in intimate life.
If you are experiencing these changes, at Procelk® we can help you assess whether this regenerative alternative could be part of your treatment.
Reduction in menopausal symptoms and better hormonal balance
When hot flashes, insomnia, irritability, fatigue, or body pain begin to affect your routine, it is not only your body that changes: the way you experience daily life changes too. Izawa and collaborators published a study in Regenerative Therapy (2025) involving 15 patients with ovarian dysfunction, where they evaluated the intravenous administration of autologous stem cells derived from menstrual blood. After treatment, almost all patients showed a marked reduction in symptoms from the first month, with sustained improvement through 6 months; in addition, the simplified menopausal symptom index decreased significantly. A trend toward increased estradiol and decreased FSH was also observed, more clearly in postmenopausal patients.
The treatment not only helped patients feel better, but also supported more favorable hormonal regulation, opening a more comprehensive possibility for restoring well-being.
In panel (A), the microscopy images show how the cells evolve from day 2 to day 28 in culture. From early stages, they adopt a characteristic elongated, fibroblast-like morphology, and over time they form a more organized and homogeneous population. This pattern is not incidental: it is typical of mesenchymal stem cells under optimal conditions, indicating stability, viability, and cellular expansion capacity. In panel (B), flow cytometry confirms the purity of the cellular population. The cells positively express markers such as CD73, CD90, and CD105, considered international standards for identifying mesenchymal stem cells. This validates that it is not an undefined cell mixture, but a well-characterized population.
If you are looking for much more than weight control, at Procelk® you will find a different way to care for your body.
I want to understand what happens in my bodyClinical benefit
Glycemic control
More patients achieved glycemic control and better blood stability with this cellular approach
Living with type 2 diabetes is not just about dealing with high numbers: it also means managing glucose highs and lows that are exhausting, stressful, and increase the risk of complications over time. Zang and collaborators published a phase II randomized, placebo-controlled trial in Stem Cells Translational Medicine (2023), in which they evaluated intravenous infusion of mesenchymal stem cells derived from umbilical cord tissue in 73 adults with type 2 diabetes. After 48 weeks, the treated group showed more marked improvement than placebo in both time in glycemic range and HbA1c; in addition, more patients achieved the combined goal of TIR ≥70% and HbA1c <7% at weeks 9 and 48 (59.5% vs 27.8% and 43.2% vs 11.1%).
This suggests more stable blood glucose throughout the day, fewer harmful spikes, and more favorable metabolic control for living with greater peace of mind and long-term protection.
Clinical benefit
Insulin resistance modulation
More patients were able to lower their glycated hemoglobin and cut their insulin use in half after treatment at Procelk®
Living with type 2 diabetes often means a constant routine of medications, adjustments, and the concern that, even with effort, metabolic control may still not be enough.
Li Zang and collaborators published a phase II randomized, double-blind, placebo-controlled trial in Stem Cell Research & Therapy (2022) in Chinese adults with type 2 diabetes, where they evaluated intravenous infusion of mesenchymal stem cells derived from umbilical cord tissue. At 48 weeks, 20% of treated patients achieved the combined goal of HbA1c below 7% and at least a 50% reduction in daily insulin, versus 4.55% in placebo; in addition, HbA1c decreased by 1.31% in the treated group, and insulin resistance also improved.
This suggests better blood sugar control with less dependence on insulin and a more favorable metabolic response, opening a real possibility of moving forward with greater stability.
If you are looking for regenerative alternatives for type 2 diabetes, at Procelk® we can help you evaluate your case.
Clinical benefit
Reduction of systemic inflammation
Better quality of life, more strength, and better mobility in patients with aging-related frailty
When the body begins to lose endurance, balance, and energy, it is not only movement that changes: confidence in daily life changes too. Zhu and collaborators published a phase I/II randomized, double-blind, placebo-controlled study in Stem Cell Research & Therapy (2024), in which they evaluated intravenous infusion of mesenchymal stem cells derived from umbilical cord tissue in patients with aging-related frailty. The results showed significant improvements in the physical component of quality of life from the first post-treatment visit and sustained through 6 months, as well as progress in functional tests such as Timed Up and Go and grip strength, especially toward the end of follow-up. TNF-α and IL-17 also decreased versus placebo, with no differences in adverse event incidence.
This suggests real support for regaining mobility, strength, and a sense of well-being, while reducing part of the chronic inflammation that accompanies physical decline.
Next step